Navigation Links
Omeros Commences Initial Public Offering of Common Stock
Date:9/18/2009

SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Omeros Corporation today announced the launch of its initial public offering of 6.82 million shares of its common stock. Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.

The estimated price range for the initial public offering is $10.00 to $12.00 per share. Omeros has applied to have the shares of common stock listed on The NASDAQ Global Market under the ticker symbol "OMER." The underwriters have the option to purchase up to an additional 1.02 million shares to cover over-allotments, if any. All of the shares of common stock will be offered by Omeros.

Omeros intends to use the net proceeds of the offering to fund the completion of its Phase 3 clinical trials of OMS103HP, its lead product candidate being evaluated for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain, as well as the potential launch and commercialization of OMS103HP. The Company also intends to use the net proceeds to fund the development of its other product candidates in the clinic, OMS302 for ophthalmology and OMS201 for urology, and the development of its pipeline of preclinical programs.

Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Wedbush PacGrow Life Sciences will be acting as the co-lead manager, Canaccord Adams Inc. and Needham & Company, LLC will be acting as co-managers, and Chicago Investment Group, LLC and National Securities Corporation will be acting as junior co-managers. The offering will be made only by means of a prospectus.

Copies of the preliminary prospectus may be obtained by contacting: Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telepho
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
2. Omeros Appoints New Vice President of Clinical Development
3. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. Omeros and BlueCrest Announce $20 Million Debt Facility
6. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
7. Omeros Appoints David A. Mann to its Board of Directors
8. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
9. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
10. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
11. PCI Biotech Commences Phase I/II Trials of Amphinex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... PLAINSBORO, N.J. (PRWEB) May 21, 2015 ... initial circulation audit and been admitted to BPA ... result, BPA Worldwide will track audience data for ... geographic coverage. , “By becoming a member ... steadfast dedication to providing our clients with the ...
(Date:5/21/2015)... 21, 2015 Imagine being able ... and those of others. Being able to read faces ... read people to anticipate their thoughts and actions like ... and feelings to create unique abstract paintings and video, ... Get inside a first-person-shooter as it creates action, dialog, ...
(Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) ... in HW_Technical Insights" report to their offering. ... trends in the Health and Wellness sector and has ... an impact in the year 2015. The research service ... health and wellness technologies that are anticipated to have ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Global Survey on Flow Cytometry Adoption Trends 2015 2Top Technologies in the Health and Wellness Industry 2015 2
... teams responding to the devastation across Greece caused by ... A series of crisis map products based on satellite ... damage assessment efforts following the activation of the International ... 60 people were killed and thousands left homeless in ...
... Ill. --- An innovative and inexpensive way of ... in novel forms of advanced materials that pave ... The new fabrication technique, known as soft lithography, ... the ability to scale-up the manufacturing process to ...
... Girardet Promoted to Vice President, Research Operations ... a New Non-Profit Foundation, CARLSBAD, Calif., Oct. ... a company focused on the discovery and,development of ... and inflammatory diseases, today announced changes to its,research ...
Cached Biology Technology:Greeks get space-based help in wake of deadly fires 2Nanofabrication method paves way for new optical devices 2Ardea Biosciences Announces Changes to Research Management 2Ardea Biosciences Announces Changes to Research Management 3
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Leadership Strengthened with Clinical ... Standards-Based Data Management, WHIPPANY, N.J. and ATLANTA, ... it agreed to terms to acquire Zurich,Biostatistics, Inc. ... regulatory submissions, the acquisition further strengthens,ISI,s Clinical Data ...
... SHORES, Calif., Sept. 10 ,Communication Intelligence Corporation (OTC ... signature solutions for business process,automation in the financial ... announced today the appointment of Michael Betts to,the ... over 30 years of experience in the insurance ...
... J. Michael McConnell, Director of,National Intelligence and ... Intelligence will provide valuable insights into the intelligence,challenges ... the United States,Intelligence Community 100 Day Plan for ... The Office of the Director of National Intelligence ...
Cached Biology News:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 3
... V is a fully integrated system ... image processing that deliver excellent quality microarray ... high quality microarray scanner that is based ... optimal background rejection and spatial resolution. The ...
... Synaptogyrin 2 ( Abpromise ... Antigen: Synthetic ... sequence amino acids 42-57 of ... Entrez Gene ID: ...
...
... High signal and low background ,This ... several ten times higher than obtained with ... optimized for primary and secondary antibodies, which ... S/N ratio. , Wide versatility ,It ...
Biology Products: